We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Accuracy of New Dengue Capture Assay Evaluated

By LabMedica International staff writers
Posted on 08 Apr 2015
Dengue disease has become a major global public health concern, but an ideal diagnostic test that permits early and rapid diagnosis is not yet available, so improving diagnostic performance in this area is a major challenge.

The kinetics of dengue infection in serum is accorded by virus isolation and nucleic acid or antigen detection which are the most specific diagnostic methods during the early acute stage of disease, while serology is often used for diagnosis later in the course of infection. More...


Scientists at the Pasteur Institute (Cayenne, French Guiana) selected 184 sera for evaluation included two groups: a group of 134 sera from confirmed dengue-infected patients and a second group of 50 sera from non-dengue infected patients. Sera were classified according to the onset of fever. Day zero was defined as sera collected within 24 hours after the onset of fever. Detection of specific dengue immunoglobulin M (IgM) was carried out using an in-house IgM capture enzyme-linked immunosorbent assay (MAC-ELISA).

The dengue virus (DENV) nonstructural protein (NS1) antigen was detected using the commercial Platelia Dengue NS1 AG antigen-capture enzyme-linked immunosorbent assay (ELISA) (Bio-Rad Laboratories; Marnes La Coquette, France). The Bio-Rad Platelia Dengue IgA Capture is a microplate immunoassay using immuno-capture format for detection of specific IgA against DENV in human serum or plasma. Detections of specific dengue IgM and IgG were carried out using the Panbio Dengue IgM Capture ELISA and the Panbio Dengue IgG Capture ELISA kits (Panbio; Brisbane, Australia).

Out of the 134 dengue group sera, the IgA index assay detected 124 positive, indicating a sensitivity of 93%. Six sera out of the 50 non-dengue group ones were also found IgA positive, demonstrating a specificity of 88%. Seropositivities for IgA broadly increased from 50% for sera collected three to four days after the onset of fever to 100% for those collected seven days after. The IgA test had very good sensitivity for detecting infections caused by three dengue serotypes (DENV-2, DENV-3, DENV-4, with sensitivities of 100%, 97% and 92% respectively), while its ability to detect infection caused by DENV-1 was significantly less efficient (85%). The IgA assay had a good concordance with the Panbio IgM capture ELISA.

The authors concluded that the Platelia Dengue IgA Capture assay is an acceptable test, with overall sensitivity and specificity of about 90%. The IgA test assay is a more accurate dating of infection when used to measure a good quality serological marker detectable in acute-phase serum and persisting for a shorter period of time than dengue specific IgM allows. The study was published on March 24, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Pasteur Institute
Bio-Rad Laboratories
Panbio 



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
TRAb Immunoassay
Chorus TRAb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.